Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon secretion. GLP-1 peptides exhibit promising therapeutic results in treating type 2 d